ClinicalTrials.gg

Program

TLL-018

A development code. Also written as “TLL-018 tablets”, “TLL018 tablets” and “TLL-018 extended-release tablet”.

Its studies are mostly in Arthritis, Rheumatoid · Chronic Urticaria · Dermatitis, Atopic · Psoriasis · Colitis, Ulcerative, led by 2 companies.

Furthest: phase 3, since Aug 25, 202313 company-led studies, 6 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hangzhou Highlightll Pharmaceutical126 open or runningphase 3since Aug 25, 2023Nov 15, 2021Dec 31, 2026phase 3 · NCT06887127
TLL Pharmaceutical10 open or runningphase 2since Nov 5, 2021Nov 5, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 5, 2021First study: phase 2 study in Colitis, UlcerativeNew to TLL PharmaceuticalTLL Pharmaceutical · NCT05121402 · United States
  2. Nov 15, 2021Hangzhou Highlightll Pharmaceutical's first study: phase 2 study in Arthritis, RheumatoidNew to Hangzhou Highlightll PharmaceuticalHangzhou Highlightll Pharmaceutical · NCT05133297 · 101 enrolled · China
  3. Apr 7, 2022Phase 1 study in Moderate to Severe Plaque PsoriasisHangzhou Highlightll Pharmaceutical · NCT05342428 · 73 enrolled · China
  4. May 10, 2022Phase 1 study in Chronic UrticariaHangzhou Highlightll Pharmaceutical · NCT05373355 · 41 enrolled · China
  5. Mar 6, 2023Phase 2 study in Plaque PsoriasisHangzhou Highlightll Pharmaceutical · NCT05772520 · 82 enrolled · United States
  6. Jul 5, 2023Phase 1 study in Dermatitis, AtopicHangzhou Highlightll Pharmaceutical · NCT05945810 · 28 enrolled · China
  7. Aug 25, 2023Phase 3 study in Arthritis, RheumatoidHangzhou Highlightll Pharmaceutical · NCT06020144 · 459 enrolled · China
  8. Apr 29, 2024Phase 3 study in Chronic UrticariaHangzhou Highlightll Pharmaceutical · NCT06396026 · 440 enrolled · China
  9. Mar 14, 2025Phase 3 study in Arthritis, RheumatoidHangzhou Highlightll Pharmaceutical · NCT06887127 · 350 enrolled · China
  10. Jun 18, 2026Phase 2 study in Chronic UrticariaHangzhou Highlightll Pharmaceutical · NCT07665996 · 36 planned · China
  11. Jul 31, 2026Phase 2 study in Arthritis, RheumatoidHangzhou Highlightll Pharmaceutical · NCT07748728 · 90 planned · China
  12. Aug 9, 2026Phase 2 study in Chronic UrticariaHangzhou Highlightll Pharmaceutical · NCT07764003 · 140 planned
  13. Aug 21, 2026Phase 3 study in Dermatitis, AtopicHangzhou Highlightll Pharmaceutical · NCT07784816 · 390 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Arthritis, RheumatoidHangzhou Highlightll Pharmaceutical · NCT06887127
  2. Jul 31, 2027Primary completion: phase 2 study in Arthritis, RheumatoidHangzhou Highlightll Pharmaceutical · NCT07748728
  3. Dec 31, 2027Primary completion: phase 2 study in Chronic UrticariaHangzhou Highlightll Pharmaceutical · NCT07764003
  4. Dec 31, 2027Primary completion: phase 2 study in Chronic UrticariaHangzhou Highlightll Pharmaceutical · NCT07665996

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07784816Dermatitis, Atopic · China3Not yet recruitingHangzhou Highlightll PharmaceuticalSep 30, 2029390
NCT07764003Chronic Urticaria2Not yet recruitingHangzhou Highlightll PharmaceuticalDec 31, 2027140
NCT07748728Arthritis, Rheumatoid · China2By invitationHangzhou Highlightll PharmaceuticalJul 31, 202790
NCT07665996Chronic Urticaria · China2Not yet recruitingHangzhou Highlightll PharmaceuticalDec 31, 202736
NCT06887127Arthritis, Rheumatoid · China3Active, not recruitingHangzhou Highlightll PharmaceuticalDec 31, 2026350
NCT06396026Chronic Urticaria · China3Active, not recruitingHangzhou Highlightll PharmaceuticalOct 23, 2025440
NCT06020144Arthritis, Rheumatoid · China3CompletedHangzhou Highlightll PharmaceuticalJan 15, 2026459
NCT05945810Dermatitis, Atopic · China1CompletedHangzhou Highlightll PharmaceuticalAug 28, 202328
NCT05772520Plaque Psoriasis · United States2CompletedHangzhou Highlightll PharmaceuticalDec 1, 202482
NCT05373355Chronic Urticaria · China1CompletedHangzhou Highlightll PharmaceuticalSep 7, 202341
NCT05342428Moderate to Severe Plaque Psoriasis · China1CompletedHangzhou Highlightll PharmaceuticalAug 30, 202373
NCT05133297Arthritis, Rheumatoid · China2CompletedHangzhou Highlightll PharmaceuticalDec 19, 2022101
NCT05121402Colitis, Ulcerative · United States2WithdrawnTLL PharmaceuticalJul 1, 20230

How it is read

Names in the registry

  • “TLL-018”, 8 entries
  • “TLL-018 tablets”, 6 entries
  • “TLL018 tablets”, 3 entries
  • “TLL-018 extended-release tablet”, 1 entry
  • “TLL-018 immediate-release tablet”, 1 entry

Codes read as this program: TLL018.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.